Pharmamar en el Congreso 2017 de la Europea Society of Gynecological Oncology ( ESGO 20 ) .

PharmaMar will present at ESGO new data on Yondelis® for Gynecological Cancers .

*.- PharmaMar will present a study on the efficacy of Yondelis® in women with ovarian cancer at the European Society of Gynecological Oncology (ESGO) congress

*.- PharmaMar will organize a satellite symposium in which there will be a debate on whether quality of life of ovarian cancer patients is a key factor in the taking of decisions

Madrid, November 3rd, 2017.- PharmaMar (MSE:PHM) will announce the data obtained from a Phase IV clinical trial of its antitumor compound of marine origin, Yondelis®, during the European Society of Gynecological Oncology Congress (ESGO), that will be held from the 4th to the 7th of November in Vienna.

...

Saturday, November 4, 2017

13:00 -14:30

Hall B

THE KEY ROLE OF QUALITY OF LIFE IN THE LONG-DISTANCE RACE OF OVARIAN CANCER

Symposium Organized by: PharmaMar

CHAIR: Andreas Du Bois, Germany

13:00   WELCOME AND INTRODUCTION
Andreas Du Bois, Germany

13:05   SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
Felix Hilpert, Germany

13:25    BEING PRACTICAL

Case 1:  Isabelle Ray-Coquard , France
Case 2:  Nicoletta Colombo, Italy
Case 3: Christian Marth, Austria

14.25     CLOSING AND REMARKS
Andreas Du Bois, Germany